BlueRock Therapeutics’ President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company’s Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.
Related News
Research Insights
A Strategy to Compare Single-Cell RNA Sequencing Data Sets Provides Phenotypic Insight into Cellular Heterogeneity Underlying Biological Similarities and Differences Between Samples
October 8, 2024
Research Insights
